Low-dose oral interferon-α in the treatment of chronic viral hepatitis type B: A double-blind, randomized, placebo-controlled, clinical trial

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 5, 2000, Pages 245-254

  Yasuda, Kiyomi ^a   Ohashi, Yasuo ^b   Matsushima, Takashi ^c   Kumada, Hiromitsu ^d   Hino, Kunihiko ^e   Ito, Madoka ^f   Takeuchi, Toshihiko ^g   Kakumu, Shinichi ^h   Kuroki, Tetsuo ⁱ   Hayashi, Norio ^j   Sata, Michio ^k   Iino, Shiro ^l  

^a Seizankai Kiyokawa Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Hakodate Municipal Hospital   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e HRI Ltd   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NTT West Tokai Hospital Nagoya   (Japan)

^h AICHI MEDICAL UNIVERSITY   (Japan)

ⁱ OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^k KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Hepatitis B virus; Hepatitis B virus marker; Oral interferon ; Randomized controlled trial

Indexed keywords

ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEPATITIS B; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URTICARIA;

EID: 0034084821     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80015-6     Document Type: Article

References (26)

1. 1. Cummins JM, Tompkins MB, Olsen RG, et al. Oral use of human alpha interferon in cats. J Biol Response Mod. 1988;7:513-523.
2. 2. Young AS, Maritim AC, Kariuki DP, et al. Low-dose oral administration of human interferon alpha can control development of Theileria parva infection in cattle. Parasitology. 1990;101:201-209.
3. 3. Cummins JM, Hutcheson DP, Cummins MJ, et al. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch Immunol Ther Exp. 1993;41:193-197.
4. 4. Brod SA, Scott M, Burns DK, et al. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type I interferons. J Interferon Cytokine Res. 1995;15:115-122.
5. 5. Brod SA, Khan M. Oral administration of IFN-α is superior to subcutaneous administration of IFN-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun. 1996;9:11-20.
6. 6. Brod SA, Khan M, Kerman RH, et al. Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol. 1995;58:61-69.
7. 7. Yoshino S. Suppression of adjuvant arthritis in rats by oral administration of type II collagen in combination with type I interferon. J Pharm Pharmacol. 1996;48:702-705.
8. 8. Yoshino S. The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Exp Mol Pathol. 1995;62:123-130.
9. 9. Hutchinson VA, Cummins JM. Low-dose oral interferon in patient with AIDS. Lancet. 1987;2:1530-1531.
10. 10. Koech DK, Obel AO, Minowada J, et al. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-I (HIV-1). Mol Biother. 1990;2:91-95.
11. 11. Koech DK, Obel AO. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). East Afr Med J. 1990;67(Suppl 2):SS64-SS71.
12. 12. Jordan WC. Three open-label studies of oral interferon alpha in the treatment of HIV disease. J Natl Med Assoc. 1994;86:257-262.
13. 13. Caban J, Mossor-Ostrowska J, Zyrkowska-Bieda T, et al. Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges. Arch Immunol Ther Exp. 1993;41:229-235.
14. 14. Zielinska W, Paszkiewicz J, Korczak A, et al. Treatment of fourteen chronic active HBsAg + HBeAg + hepatitis patients with low dose natural human interferon alpha administered orally. Arch Immunol Ther Exp. 1993;41:241-251.
15. 15. Georgiades JA, Caban J, Zyrkowska-Bieda T, et al. Natural human interferon α given orally has different effects on patients with distinct forms of chronic viral hepatitis B. Arch Immunol Ther Exp. 1996;44:187-194.
16. 16. Zielinska W, Paszkiewicz J, Korczak A, et al. Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally. Arch Immunol Ther Exp. 1993;41:253-257.
17. 17. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjögren syndrome. J Interferon Cytokine Res. 1998;18:255-262.
18. 18. Watanabe Y, Hino K, Yasuda K, et al. Detection of HBV-DNA by bDNA probe assay and its clinical relevance. Iyaku to Yakugaku. 1993;30:1217-1226.
19. 19. Hosotsubo H, Deguchi M, Ohmine T, et al. Quantitation measurement of serum hepatitis B virus DNA (HBV-DNA) by branched DNA probe assay using chemiluminescence. Iyaku to Yakugaku. 1994;31:743-751.
20. 20. Kurai K, Iino S, Koike K, et al. Quantitative measurement of hepatitis B e antigen by enzyme immunoassay. Acta Hepatol Jpn. 1984;25:483-490.
21. 21. Realdi G, Alberti A, Rugge M, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology. 1980;79:195-199.
22. 22. Sodeyama K. Clinical significance of HBeAg/anti-HBe system in HBsAg positive chronic hepatitis. Acta Hepatol Jpn. 1982;23:731-741.
23. 23. Kurai K, Iino S, Suzuki H, et al. Long-term follow-up study of chronic hepatitis B virus carriers with and without hepatitis. Acta Hepatol Jpn. 1984;25:1394-1405.
24. 24. Nagao Y, Yamashiro K, Hara N, et al. Oral-mucosal administration of IFN-α potentiates immune response in mice. J Interferon Cytokine Res. 1998;18:661-666.
25. 25. Beilharz MW, McDonald W, Watson MW, et al. Low-dose oral type 1 interferons reduce early virus replication of murine cytomegalovirus in vivo. J Interferon Cytokine Res. 1997;17:625-630.
26. 26. Georgiades JA, Flischmann WR Jr. Oral application of cytokines. Biotherapy. 1996;8: 205-212.